Single-cell immunophenotyping of the fetal immune response to maternal SARS-CoV-2 infection in late gestation

Juan Matute (✉ jmatute@mgh.harvard.edu)

Massachusetts General Hospital and Harvard Medical School <https://orcid.org/0000-0002-1703-8115>

Benjamin Finander

Boston Children's Hospital and Harvard Medical School

David Pepin

Massachusetts General Hospital

Xinbin Ai

Massachusetts General Hospital and Harvard Medical School

Neal Smith

Massachusetts General Hospital and Harvard Medical School

Jonathan Li

Harvard Medical School <https://orcid.org/0000-0001-9914-9662>

Andrea Edlow

Massachusetts General Hospital and Harvard Medical School

Alexandra Villani

Harvard University

Paul Lerou

Massachusetts General Hospital and Harvard Medical School

Brian Kalish

The Hospital for Sick Children and University of Toronto

Article

Keywords: COVID19, SARS-CoV-2, pregnancy, cord blood mononuclear cells

Posted Date: March 16th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-311000/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Pediatric Research on November 8th, 2021.
See the published version at <https://doi.org/10.1038/s41390-021-01793-z>.

Abstract

During the COVID-19 pandemic, thousands of pregnant women have been infected with SARS-CoV-2. The implications of maternal SARS-CoV-2 infection on fetal and childhood well-being are unknown. We aimed to characterize the fetal immune response to maternal SARS-CoV-2 infection. We performed single-cell RNA sequencing and T-cell receptor (TCR) sequencing on cord blood mononuclear cells (CBMC) from newborns of mothers infected with SARS-CoV-2 in the third-trimester (cases) or without SARS-CoV-2 infection. We identified widespread gene expression changes in CBMC from cases, including upregulation of interferon-stimulated genes and Major Histocompatibility Complex genes in CD14 + monocytes; transcriptional changes suggestive of activation of plasmacytoid dendritic cells, and activation and exhaustion of NK cells and CD8 + T-cells. Lastly, we observed fetal TCR repertoire expansion in cases. As none of the infants were infected with SARS-CoV-2, our results suggest that SARS-CoV-2 maternal infection might modulate the fetal immune system in the absence of vertical transmission.

Introduction

Millions of people worldwide have or will become infected with SARS-CoV-2, causing Coronavirus Disease 2019 (COVID-19), and the infection of pregnant women with SARS-CoV-2 infection has been widespread^{1–6}. Despite the prevalence of antepartum infection, we have a limited understanding of the implications of SARS-CoV-2 infection on maternal, fetal, and offspring health. To date, there are limited case reports of vertical, mother-to-child transmission of SARS-CoV-2^{7–12}, and vertical transmission remains rare in most pregnancies complicated by maternal SARS-CoV-2 infection^{1,6,13–17}. Nonetheless, in the absence of direct fetal infection and toxicity, maternal SARS-CoV-2 infection may still affect fetal development. Maternal immune activation during pregnancy after viral infection without vertical transmission can have long-term consequences for the newborn, including abnormal neurologic^{18,19} or immune system development²⁰.

Pregnancy is a complex and precarious immunologic state, and there is no data on the effect of SARS-CoV-2-dysregulated immune state during pregnancy on the fetus. The related SARS-CoV epidemic in 2003 was linked to high rates of spontaneous abortions, preterm birth, and intrauterine growth restriction²¹. Given the number of pregnant women infected with SARS-CoV-2 worldwide, it is important to determine the potential transgenerational implications of infection with SARS-CoV-2 during pregnancy beyond vertical transmission. To date, research on the implications of SARS-CoV-2 infection during pregnancy on the offspring immune system has been limited to postnatal evaluation of infants born to mothers infected with SARS-CoV-2 during pregnancy without a non-exposed control group^{22,23}, which may be also confounded by *ex-utero* determinants of immune development during the first week of life²⁴. In the present study, we characterize the composition and cell type-specific transcriptional landscape of umbilical cord blood mononuclear cells (CBMC) from term gestation infants (> 37 weeks) born to mothers infected with SARS-CoV-2 in the third trimester without vertical transmission. This immunogenomic investigation provides evidence of both innate and adaptive fetal immune transcriptional changes in

pregnancies complicated by SARS-CoV-2 infection. Our results suggest that even in the absence of vertical transmission, SARS-CoV-2 maternal infection in the third trimester might modulate the fetal immune system.

Results And Discussion

To characterize the fetal immunologic landscape in pregnancies complicated by maternal SARS-CoV-2 infection, we performed droplet-based single-cell RNA sequencing (scRNAseq) of CBMC from infants born to mothers with SARS-CoV-2 infection during pregnancy (cases) and infants born to mothers without SARS-CoV-2 infection (controls). CBMCs from three cases and three controls were obtained from our biorepository²⁵. None of the three infants in this study born to mothers with SARS-CoV-2 were positive for SARS-CoV-2 postnatally, had detectable SARS-CoV-2 mRNA in placenta or developed any neonatal morbidity. All mothers with COVID19 in the third trimester were classified as having mild disease without respiratory support²⁶. Infants born to mothers negative for SARS-CoV-2 and asymptomatic (universal screening at admission for labor) during the same epoch served as controls. Maternal comorbidities were matched between cases and controls as feasible. Table 1 displays demographic and clinical data from the cases and controls.

Subjects	Onset of Symptoms (GA)	SARS-CoV-2 PCR (GA)	Delivery (GA)	Days between onset of symptoms and birth	Maternal symptoms at test	Delivery Mode	Any Labor?	Maternal Comorbidities	Sex Assigned At Birth	Placental viral load by RT-PCR	24h nasopharyngeal viral load by RT-PCR
Control 1	NA	39.9	40	NA		VD	Yes		Male	1	NA
Control 2	NA	38.9	39.4	NA		CS	Yes	BMI > 30, Thyroid disease	Female	1	NA
Control 3	NA	38.4	38.6	NA		CS	Yes	BMI > 30	Female	ND	NA
Case 1	30.3	30.7	39.7	66	Fever/Chills, nasal congestion, Loss of taste/smell, sore throat, night sweats	VD	Yes	Thyroid disease	Male	1	Negative
Case 2	34.4	35.4	40.1	40	Cough, Fever/Chills, Myalgias, Headache, chest discomfort	CS	Yes	Diabetes/GDM, BMI > 30, Thyroid disease	Male	1	Negative
Case 3	39	39.4	40	7	Cough, Fever/Chills	VD	Yes	BMI > 30	Female	1	Negative

TABLE 1:
Clinical characteristics of Cases and controls. GA: Gestational Age, VD: Vaginal Delivery, CS: Cesarean section, ND: Not done, NA: Not applicable

CBMCs were processed on the 10X Genomics Single-Cell Immune platform (see Methods). After quality control and doublet removal, we included 14,748 cells with high quality single-cell transcriptomes from cases and 11,222 cells from controls in our dataset. (See quality control metrics in Supplementary Fig. 1A-B). The cellular population composition was visualized using uniform manifold approximation and projection (UMAP, Fig. 1A), and cell types were inferred by cluster-specific canonical marker genes

(Fig. 1B-C). We did not observe any differences in cell cluster composition between cases and controls (Supplementary Fig. 1C).

To explore transcriptional signatures in fetal immune cells associated with maternal SARS-CoV-2 infection, we performed differential gene expression (DGE) analysis within cell types comparing cases and controls. Genes with a false discovery rate (FDR) < 5% were considered statistically significant. We identified hundreds of genes across nearly all cell types with altered expression (Fig. 2A). We used gene ontology (GO) analysis to broadly classify genes significantly disrupted by maternal SARS-CoV-2 infection based on DGE (Supplemental Table 1).

CD14 + monocytes were grouped into 5 clusters and CD16 + monocytes were grouped into one cluster (Fig. 2B). CD14 + sub-populations demonstrated variable expression of inflammatory genes, including *ACSL1*, *ADGRE2*, *CD300E* and *PADI4*, which aligns with prior single cell analysis showing monocyte diversity²⁷. Consistent with data from adult COVID-19 patients^{28,29}, we found that CD14 + monocytes from cases demonstrated increased expression of ISG (Fig. 2C) and concomitant *IFNAR2* downregulation (Supplemental Fig. 2a), which could reflect exposure to interferon prenatally³⁰. GO analysis of DGE in CD14 + monocytes demonstrated enrichment of genes associated with antigen presentation and viral translational termination and reinitiation (Fig. 2D). Cord blood (CB) CD14 + monocytes from cases also showed upregulation of major histocompatibility class (MHC) I and II genes suggesting activation in response to interferon signaling³¹. Furthermore, CD14 + monocytes from cases showed upregulation of TLR receptor transcripts (*TLR2*, *TLR4* and *TLR5*) paired with upregulation of *FOS* and downregulation of transcriptional inhibitors of NFkB (*NFKBIA* and *NFKBIE*), all of which are associated with increased NFkB activation and cytokine production³² (Supplemental Fig. 2A). Of note, CD14 + monocytes from cases had decreased expression of autophagy (*ATG14*, *ATG2A*, *ATG3*) and endoplasmic reticulum stress (*XBP1*, *HSPA5*) genes, which may contribute to a defect in macrophage differentiation³³ (Supplemental Fig. 2A).

Similar to CD14 + monocytes, we identified induction of ISG in non-classical CB monocytes (CD16+) (Fig. 2C). In contrast to CD14 + monocytes, we found that there was decreased expression of cell adhesion genes (including *PLAUR* and *THBS1*), attenuation of immune activation signaling pathways genes (*FOS*, *FOSB*, *MAP3K8*, *STAT6*, and *FCER1G*), and decreased expression of inflammatory molecules like resistin (*RETN*) (Supplemental Fig. 2B). Together, these results suggest induction of ISG in monocytes from cases compared to controls and differences in transcriptional changes in classical and non-classical monocytes that might suggest preferential activation of classical monocytes in cases compared to controls.

We captured the transcriptomes of both plasmacytoid and conventional dendritic cells (pDC and cDC, respectively) in CB. In adults infected with SARS-CoV-2, both types of DCs are functionally impaired, and there is an increased ratio of cDCs to pDCs in severe patients³⁴. In our study, CB cDC from cases showed increased expression of ISG like *IFITM3* and *APOBEC3A* (Fig. 2E). Transcription factor zinc finger E box-binding homeobox 2 (*Zeb2*) plays a crucial role in promoting cDC and pDC development by downregulating Inhibitor of DNA binding protein 2 (*ID2*)^{35,36}. *ZEB2* was increased in cDC and *ID2* was

decreased in pDC from CB of cases, which might be evidence of a shift towards pDC in CB from infants exposed to SARS-CoV-2 *in utero* (Fig. 2E). Fetal cDC from cases showed a transcriptional profile suggestive of innate immune activation including increased expression of *PIK3CB*, which is downstream of TLR5 and TLR7³⁷, as well as increased transcription of *CCL5*, which can be upregulated after TLR3 stimulation (Fig. 2E)³⁸. Evidence of impaired cDC maturation was suggested by upregulation of *ID1*, which antagonizes dendritic cell differentiation and antitumor immunity in mice³⁹, as well as increased *MAFB* transcription, which suppresses cDC maturation⁴⁰. cDCs from cases also demonstrated decreased expression of *FOSB* and many MHC II genes⁴¹. pDCs in cases also showed markers of immune activation, including upregulation of *RELB*, which promotes DC activation through RelB-p50 dimer⁴², upregulation of MHC Class I and Class II genes, and UPR activation, as shown by increased transcription of *XBP1*⁴³ (Supplemental Fig. 2C). Together, these transcriptional findings could be consistent with activation of pDC over cDC in the CB of cases, potentially through activation of TLRs.

In adults, SARS-CoV-2 infection is associated with fewer blood NK cells but a higher activation state in circulating NK cells⁴⁴. We identified two clusters of cord blood NK cells. One population of NK cells (cluster 1) expressed higher levels of *GZMB*, while the second population of NK cells (cluster 2) expressed *IL7R* and *XCL1*, suggesting that cluster 1 corresponded to CD56dim and cluster 2 corresponded to CD56bright NK cells, as *NCAM1* (CD56) is technically not well captured in scRNAseq⁴⁵. Similar to adult NK cells, CB NK cells from SARS-CoV-2-positive pregnancies showed signs of exposure to interferon, including induction of ISG genes like *IFI6*, *IFIT2* and *IRF9* (Fig. 2F)^{44,46,47}. We identified increased transcription of *CCL4*, expression of cytotoxic genes including *GNLY*, *GZMA*, *GZMB* and *GZMH*, and increased transcription of *IFNG*, paired with decreased expression of NK inhibitory molecules (Fig. 2F)^{44,46,47}. There were transcriptional changes associated with exhaustion, such as decreased expression of *KLRG1* and *SIGLEC7*⁴⁸. DGE in NK cells between cases and controls were enriched for genes related to the interferon-alpha response, regulation of NK cell cytokine production, and viral transcription (Fig. 2G).

In adults with acute COVID19, there is a heterogeneous adaptive immune response in peripheral blood, including B-cell receptor and T-cell receptor arrangements specific to SARS-CoV-2⁴⁶. Given these findings, we evaluated whether maternal infection with SARS-CoV-2 had any effect on CB lymphocyte gene expression. We were able to identify three clusters of CB B-cells (Fig. 1A,B). We also identified three clusters of T-cells (Fig. 3A). Cluster 1 corresponded to CD8 + T-cells. Cluster 2 and 3 corresponded to helper T cells⁴⁹. Increased expression of *CCR7* in T-cell Cluster 2 suggests this cluster includes either naive T-cells or central memory T-Cells⁵⁰ and increased *CTSW* and *KLRB1* in Cluster 3 suggest this cluster includes effector and memory T-cells^{51,52}.

In B cells from infants exposed to SARS-CoV-2 *in utero*, we identified 3 clusters of CB B-cells corresponding to non-plasma (Cluster 1 and 2) and plasma cells (Cluster 3) based on *MZB1* expression⁴⁶ (Supplementary Fig. 2D). In B-cells from infants born to mothers infected with SARS-CoV-2, we identified

decreased markers of B-cell receptor activation in all clusters. Specifically, we found decreased transcription of *NR4A1*, *CD69* and *CD83* in all B-cells (Supplemental Fig. 2E). *NR4A1* encodes Nur77, an orphan nuclear receptor, that is induced upon B-cell activation in peripheral blood in humans⁵³. *CD83* is expressed upon activation of B-cells, and activated T-cells induce CD83 on B-cells via CD40 engagement⁵⁴. Concordant with decreased B-cell activation, we also found downregulation of *CD69*⁵⁵, decreased expression AP-1 and NFAT genes⁵⁶, and decreased expression of anti-apoptotic genes, including *BCL2* and *BCL2A1*⁵⁷ (Supplemental Fig. 2E). Transcriptional changes suggestive of potential B-cell dysfunction, combined with decreased transplacental transmission of IgG against SARS-CoV-2 compared to IgG against other antigens^{6,58}, might translate into potential impairments in antibody mediated immunity to SARS-CoV-2 in neonates born to mothers with COVID19.

In adults with COVID19, CD8 + T-cells show decreased cytotoxic potential and exhaustion driven by IL-6⁵⁹. Similar to adults, CB CD8 + T-cells from cases demonstrated transcriptional signatures suggestive of impaired cytotoxic activity, including decreased expression of *GZMA*⁶⁰, and CD8 T-cell exhaustion, including downregulation of *FOS* (Fig. 3B)⁶¹. Furthermore, there was increased expression of genes associated with central memory T-cells, including *KLRB1*⁵² and *CCR7*⁶², that might be associated with fetal CD8 activation with SARS-CoV-2 (Fig. 3B). GO analysis of DGEs in CD8 + T-cells demonstrated enrichment for genes associated with T-cell tolerance, proliferation, and the response to interferon gamma (Supplemental Fig. 3A). In T-cell Cluster 2, we found increased expression of IL6-IL17 axis genes including *RORA*, *ARID5A*, *RBPJ*, and *IL6ST* in cases compared to controls (Supplemental Fig. 3B). IL6-IL17 axis has been implicated in mediating the neurodevelopmental effects of maternal immune activation in mice⁶³.

T-cell antigen receptor (TCR) repertoire in T-cells reflects selection by self and foreign antigens. To investigate the repertoire of TCRs in CB from SARS-CoV-2-exposed pregnancies and controls, we performed single cell TCR sequencing. A total of 1,943 T-cells were analyzed, and T-cells with TCR information were well equally distributed between subject and T-cell populations (Supplemental Fig. 3C and 3D). Clonal expansion was significantly increased in T-cells from pregnancies complicated by maternal SARS-CoV-2 infection, with 40.4% of T-cells having > 5 clones in the cases, compared with 30.9% in the controls (Kolmogorov-Smirnov Test p value 2.2e-16) (Fig. 3D). The T-cell clonal expansion in CB from cases is consistent with results of T-cell repertoire analysis from adults infected with SARS-CoV-2⁴⁶.

Despite the novelty of scRNAseq analysis of CBMC, our study is exploratory and has several limitations. Importantly, the small number of samples limits the generalizability of our conclusions. However, few studies have evaluated CB immune populations by single-cell transcriptomics^{64,65}, and our results illustrate an important and potentially underrecognized population in the COVID-19 pandemic that should be further studied. All cases included in this study were classified as mild maternal SARS-CoV-2 infection; more severe maternal infection could result in more dramatic or different fetal immune genomic signatures. Furthermore, the time from infection to delivery and cord blood collection likely affects the immune phenotype observed in cord blood. As the time of maternal infection and birth in our cohort

fluctuates between 7 and 66 days, more pronounced findings could be found with samples with a more consistent timing between infection and collection. Lastly, all mothers affected with SARS-CoV-2 in our cohort had comorbidities including well-controlled thyroid dysfunction, obesity or gestational diabetes. Although we included mothers with similar comorbidities in the control population (except for gestational diabetes) and all these comorbidities were medically managed, it is possible that our results are influenced by the comorbidities of the mothers. However, thyroid disease, obesity or gestational diabetes in the mother have not been reported to trigger the transcriptional response patterns we observed in cases compared to controls^{66–69}.

Despite these limitations, the present study identifies transcriptional changes suggestive of a fetal immune response after maternal infection with SARS-CoV-2 in the absence of vertical transmission and suggest potential trans-placental immune implications of maternal SARS-CoV-2 infection beyond vertical transmission. The source of signals promoting transcriptional changes in neonatal monocytes and other immune cells in the absence of vertical transmission is unknown. *Ex-vivo* studies have shown that transplacental transfer of IL1 β , IL6 and TNF does not occur⁷⁰. Type I interferons are increased in peripheral circulation of patients with mild COVID19²⁸, but the ability of interferon to cross the human placenta is unclear⁷¹. Our results raise the possibility that pro-inflammatory signaling in the mother in response to SARS-CoV-2 might promote interferon signaling at the feto-maternal interface. Further experimental data needs to be collected to clarify how maternal infection with SARS-CoV-2 influences the fetal immune system. Given the extensive literature linking maternal immune dysregulation and abnormal fetal development in viral infections, this study raises important questions about untoward effects of maternal SARS-CoV-2 on the fetus, even in the absence of vertical transmission and highlights the need of further studies to better characterize the fetal immune response in pregnancies affected by SARS-CoV-2 infection.

Methods

Sample collection, cryopreservation and placental viral load

The subjects were six infants born at term to mothers with or without SARS-CoV-2 infection in the third-trimester. Parents of the infants provided informed consent before sample collection and study participation. The study was approved by the Institutional Review Board of the Mass General Brigham (IRB 2020P001478 and IRB2020P000804). Cord mononuclear cells were collected using ficoll and cryopreserved as described²⁵. We used DMSO as our cryopreservant agent as it adequately conserves gene expression profiles in cryopreserved cells compared to fresh cells in droplet-based single-cell RNA sequencing⁷². We excluded preterm infants, as a strong proinflammatory signature in CB has been reported in infants born preterm⁷³. None of the infants were exposed to prenatal steroids, were diagnosed as IUGR, or had any neonatal morbidities. Placental viral load was measured as previously reported⁷⁴.

Single-cell RNA-sequencing

CBMC aliquots were thawed in a 37°C water bath and resuspended in RPMI-1640 with 10% FBS (Thermo Fisher). Samples were centrifuged at 350 x g for 7 minutes at 4°C. Cells were resuspended in 100 microliters of 1X PBS with 2.5% FBS and 2 mM EDTA.

Dead cells and red blood cells were depleted using the EasySep Dead Cell Depletion Kit and EasySep RBC Depletion Reagent (Stem Cell), according to manufacturer instructions. Cells were resuspended in RPMI/10% FBS and counted. Cells were loaded on to the 10X Chromium controller at a targeted recovery density of 10,000 cells per sample. Samples were processed and sequencing libraries were created using the 10X the Chromium Next GEM single-cell V(D)J Reagent Kit v1.1 with human TCR V(D)J Enrichment following manufacturer instructions.

Single-cell RNA-sequencing data analysis

Sequencing data were aligned to the genome and processed using the 10X Genomics Cell Ranger software, version 4.0.0. All cells were combined into a single dataset. Doublets were removed using Scrublet version 0.2.1, and the remaining cells were re-clustered. Mitochondrial genes were filtered from the dataset. Cells with fewer than 250 or more than 2500 unique genes were excluded. Cells were then clustered using the Seurat R package (Version 3.2.3). Specifically, the SCT functionality of Seurat was used to identify cell types that did not depend upon unique aspects of individual samples. Clustering resolution was set to 0.8, and the first 15 principal components were used. The data were log normalized and scaled to 10,000 transcripts per cell. The expression of known marker genes was used to assign each cluster to one of the main cell types. The Seurat FindMarkers function was used to identify genetic markers of cellular subtypes.

Identification of differentially expressed genes between cases and controls

To identify differentially expressed genes by cell type, we performed a differential gene expression analysis using Monocle2. The analysis was conducted on each cell type and also certain unions of cell types with common traits. The data were modeled and normalized using a negative binomial distribution, and counts data was normalized for gene length and read depth. Genes whose false discovery rate (FDR) was less than 5% were considered statistically significant. GO analysis was performed using gprofiler2 version 0.2.0, and terms were selected from the Biological Process category of GO terms.

T cell receptor sequencing

TCR sequencing data was analyzed using the R package scRepertoire (Version 3.12).

Declarations

AUTHOR CONTRIBUTIONS

JDM and BTK conceived and designed the study. JDM, BTK, DP, XA, JZL and AGE performed experiments and acquired data. ACV provided essential protocols. JDM, BTK, BF, NPS, AGE and ACV analyzed data. JDM and BTK drafted the manuscript, and all authors edited the manuscript. JDM, XA, AGE, and PHL contributed to clinical sample collection. PHL and BTK co-supervised the study.

ACKNOWLEDGEMENTS

JDM was funded Research Fellowship Award # 707702 from the Crohn and Colitis Foundation (CCF). BTK was funded by the National Institute of Neurological Disorders and Stroke (NINDS) K08 NS112338-02.

DATA AVAILABILITY

Sequencing data has been deposited in the Gene Expression Omnibus under accession GSE165193.

BRIEF SUMMARY

SARS-CoV-2 infection in the third-trimester of pregnancy without vertical transmission promotes widespread gene expression changes and TCR repertoire clonal expansion in cord blood leukocytes.

References

1. Chen, L. *et al.* Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. *New Engl J Med* **382**, e100 (2020).
2. Prabhu, M. *et al.* Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study. *Bjog Int J Obstetrics Gynaecol* **127**, 1548–1556 (2020).
3. Sutton, D., Fuchs, K., D’Alton, M. & Goffman, D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. *New Engl J Med* **382**, 2163–2164 (2020).
4. Huntley, B. J. F. *et al.* Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Systematic Review. *Obstetrics Gynecol* **136**, 303–312 (2020).
5. Ellington, S. *et al.* Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–June 7, 2020. *Morbidity Mortal Wkly Rep* **69**, 769–775 (2020).
6. Edlow, A. G. *et al.* Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. *Jama Netw Open* **3**, e2030455 (2020).
7. Raschetti, R. *et al.* Synthesis and systematic review of reported neonatal SARS-CoV-2 infections. *Nat Commun* **11**, 5164 (2020).
8. Kotlyar, A. *et al.* Vertical Transmission of COVID-19: A Systematic Review and Meta-analysis. *Am J Obstet Gynecol* (2020) doi:10.1016/j.ajog.2020.07.049.
9. Vivanti, A. J. *et al.* Transplacental transmission of SARS-CoV-2 infection. *Nat Commun* **11**, 3572 (2020).

10. Chen, H. et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet* **395**, 809–815 (2020).
11. Fenizia, C. et al. Analysis of SARS-CoV-2 vertical transmission during pregnancy. *Nat Commun* **11**, 5128 (2020).
12. Dong, L. et al. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. *Jama* **323**, 1846–1848 (2020).
13. Mascio, D. D. et al. Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM study on COVID-19. *J Perinat Med* **0**, (2020).
14. Dumitriu, D. et al. Outcomes of Neonates Born to Mothers With Severe Acute Respiratory Syndrome Coronavirus 2 Infection at a Large Medical Center in New York City. *Jama Pediatr* **175**, (2021).
15. Walker, K. et al. Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis. *Bjog Int J Obstetrics Gynaecol* **127**, 1324–1336 (2020).
16. Khoury, R. et al. Characteristics and Outcomes of 241 Births to Women With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection at Five New York City Medical Centers. *Obstetrics Gynecol* **136**, 273–282 (2020).
17. Knight, M. et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. *Bmj* **369**, m2107 (2020).
18. Al-Haddad, B. J. S. et al. Long-term Risk of Neuropsychiatric Disease After Exposure to Infection In Utero. *Jama Psychiat* **76**, 594 (2019).
19. Al-Haddad, B. J. S. et al. The Fetal Origins of Mental Illness. *Am J Obstet Gynecol* **221**, 549–562 (2019).
20. Abu-Raya, B., Kollmann, T. R., Marchant, A. & MacGillivray, D. M. The Immune System of HIV-Exposed Uninfected Infants. *Front Immunol* **7**, 383 (2016).
21. Wong, S. F. et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. *Am J Obstet Gynecol* **191**, 292–297 (2004).
22. Liu, P. et al. The immunologic status of newborns born to SARS-CoV2-infected mothers in Wuhan, China. *J Allergy Clin Immun* **146**, 101–109.e1 (2020).
23. Zeng, H. et al. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia. *Jama* **323**, 1848–1849 (2020).
24. Olin, A. et al. Stereotypic Immune System Development in Newborn Children. *Cell* **174**, 1277–1292.e14 (2018).
25. Shook, L. L. et al. Rapid establishment of a COVID-19 perinatal biorepository: early lessons from the first 100 women enrolled. *Bmc Med Res Methodol* **20**, 215 (2020).

26. NIH. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. <https://www.covid19treatmentguidelines.nih.gov/> (2020).
27. Villani, A.-C. et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. *Science* **356**, eaah4573 (2017).
28. Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* eabc6027 (2020) doi:10.1126/science.abc6027.
29. Schulte-Schrepping, J. et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. *Cell* **182**, 1419–1440.e23 (2020).
30. Arunachalam, P. S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. *Science* **369**, 1210–1220 (2020).
31. KESKINEN, P., RONNI, T., MATIKAINEN, S., LEHTONEN, A. & JULKUNEN, I. Regulation of HLA class I and II expression by interferons and influenza A virus in human peripheral blood mononuclear cells. *Immunology* **91**, 421–429 (1997).
32. Dorrington, M. G. & Fraser, I. D. C. NF- κ B Signaling in Macrophages: Dynamics, Crosstalk, and Signal Integration. *Front Immunol* **10**, 705 (2019).
33. Germic, N., Frangez, Z., Yousefi, S. & Simon, H.-U. Regulation of the innate immune system by autophagy: monocytes, macrophages, dendritic cells and antigen presentation. *Cell Death Differ* **26**, 715–727 (2019).
34. Zhou, R. et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. *Immunity* **53**, 864–877.e5 (2020).
35. Scott, C. L. et al. The transcription factor Zeb2 regulates development of conventional and plasmacytoid DCs by repressing Id2Zeb2 controls dendritic cell development. *J Exp Medicine* **213**, 897–911 (2016).
36. Wu, X. et al. Transcription factor Zeb2 regulates commitment to plasmacytoid dendritic cell and monocyte fate. *Proc National Acad Sci* **113**, 14775–14780 (2016).
37. Cavalieri, D. et al. DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells. *Immunome Res* **6**, 10 (2010).
38. Weinzierl, A. O. et al. Effective Chemokine Secretion by Dendritic Cells and Expansion of Cross-Presenting CD4⁺/CD8⁺ Dendritic Cells Define a Protective Phenotype in the Mouse Model of Coxsackievirus Myocarditis. *J Virol* **82**, 8149–8160 (2008).
39. Papaspyridonos, M. et al. Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. *Nat Commun* **6**, 6840 (2015).
40. Yang, L., Li, R., Xiang, S. & Xiao, W. MafB, a target of microRNA-155, regulates dendritic cell maturation. *Open Life Sci* **11**, 46–54 (2016).
41. Belz, G. T. & Nutt, S. L. Transcriptional programming of the dendritic cell network. *Nat Rev Immunol* **12**, 101–113 (2012).

42. Shih, V. F.-S. et al. Control of RelB during dendritic cell activation integrates canonical and noncanonical NF- κ B pathways. *Nat Immunol* **13**, 1162–1170 (2012).
43. Beisel, C. et al. TLR7-mediated activation of XBP1 correlates with the IFN α production in humans. *Cytokine* **94**, 55–58 (2017).
44. Maucourant, C. et al. Natural killer cell immunotypes related to COVID-19 disease severity. *Sci Immunol* **5**, eabd6832 (2020).
45. Yang, C. et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. *Nat Commun* **10**, 3931 (2019).
46. Zhang, J.-Y. et al. Single-cell landscape of immunological responses in patients with COVID-19. *Nat Immunol* **21**, 1107–1118 (2020).
47. Wilk, A. J. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nat Med* **26**, 1–7 (2020).
48. Varchetta, S. et al. Unique immunological profile in patients with COVID-19. *Cell Mol Immunol* 1–9 (2020) doi:10.1038/s41423-020-00557-9.
49. Ding, J. et al. Systematic comparison of single-cell and single-nucleus RNA-sequencing methods. *Nat Biotechnol* 1–10 (2020) doi:10.1038/s41587-020-0465-8.
50. Campbell, J. J. et al. CCR7 Expression and Memory T Cell Diversity in Humans. *J Immunol* **166**, 877–884 (2001).
51. Cano-Gamez, E. et al. Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4 + T cells to cytokines. *Nat Commun* **11**, 1801 (2020).
52. Fergusson, J. R., Fleming, V. M. & Klenerman, P. CD161-Expressing Human T Cells. *Front Immunol* **2**, 36 (2011).
53. Ashouri, J. F. & Weiss, A. Endogenous Nur77 Is a Specific Indicator of Antigen Receptor Signaling in Human T and B Cells. *J Immunol* **198**, 657–668 (2017).
54. Kretschmer, B., Kühl, S., Fleischer, B. & Breloer, M. Activated T cells induce rapid CD83 expression on B cells by engagement of CD40. *Immunol Lett* **136**, 221–227 (2011).
55. Zimmermann, M. et al. Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells. *Front Immunol* **10**, 829 (2019).
56. Gorter, D. J. J. de Vos, J. C. M., Pals, S. T. & Spaargaren, M. The B Cell Antigen Receptor Controls AP-1 and NFAT Activity through Ras-Mediated Activation of Ral. *J Immunol* **178**, 1405–1414 (2007).
57. Slomp, A. & Peperzak, V. Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma. *Frontiers Oncol* **8**, 533 (2018).
58. Atyeo, C. et al. Compromised SARS-CoV-2-specific placental antibody transfer. *Cell* (2020) doi:10.1016/j.cell.2020.12.027.
59. Mazzoni, A. et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. *J Clin Invest* (2020) doi:10.1172/jci138554.

60. Zhou, Z. et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. *Science* **368**, eaaz7548 (2020).
61. Wherry, E. J. et al. Molecular Signature of CD8 + T Cell Exhaustion during Chronic Viral Infection. *Immunity* **27**, 670–684 (2007).
62. Sallusto, F., Lenig, D., Förster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* **401**, 708–712 (1999).
63. Yockey, L. J., Lucas, C. & Iwasaki, A. Contributions of maternal and fetal antiviral immunity in congenital disease. *Science* **368**, 608–612 (2020).
64. Zhao, Y. et al. Single-cell transcriptomic landscape of nucleated cells in umbilical cord blood. *Gigascience* **8**, (2019).
65. Jin, X. et al. Characterization of dendritic cell subtypes in human cord blood by single-cell sequencing. *Biophysics Reports* **5**, 199–208 (2019).
66. Mason, E. et al. Maternal Influences on the Transmission of Leukocyte Gene Expression Profiles in Population Samples from Brisbane, Australia. *Plos One* **5**, e14479 (2010).
67. Svensson, J. et al. Maternal Autoimmune Thyroid Disease and the Fetal Immune System. *Exp Clin Endocr Diab* **119**, 445–450 (2011).
68. Wilson, R. M. et al. Maternal obesity alters immune cell frequencies and responses in umbilical cord blood samples. *Pediatr Allergy Immu* **26**, 344–351 (2015).
69. Yanai, S. et al. Diabetic pregnancy activates the innate immune response through TLR5 or TLR1/2 on neonatal monocyte. *J Reprod Immunol* **117**, 17–23 (2016).
70. Aaltonen, R., Heikkinen, T., Hakala, K., Laine, K. & Alanen, A. Transfer of Proinflammatory Cytokines Across Term Placenta. *Obstetrics Gynecol* **106**, 802–807 (2005).
71. Yockey, L. J. & Iwasaki, A. Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development. *Immunity* **49**, 397–412 (2018).
72. Wohnhaas, C. T. et al. DMSO cryopreservation is the method of choice to preserve cells for droplet-based single-cell RNA sequencing. *Sci Rep-uk* **9**, 10699 (2019).
73. Matoba, N. et al. Differential Patterns of 27 Cord Blood Immune Biomarkers Across Gestational Age. *Pediatrics* **123**, 1320–1328 (2009).
74. Fajnzylber, J. et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nat Commun* **11**, 5493 (2020).

Figures

Figure 1

A. UMAP of all cases and control CBMCs, with cell populations labeled by color. N=3 samples per group. B. Dot plot of marker gene expression across cell clusters. Y-axis displays marker genes, and X-axis displays cell clusters. Relative size of dots represents percentage of gene expression within a cell cluster, and relative color of dots represents average expression. C. Marker gene plots for Ms4a1 (B cells), Klr1f1 (NK cells), Lyz (Monocytes), and CD3D (T cells). Colored dots indicate gene expression.

Figure 2

A. Strip plot displaying differential gene expression between cases and controls. Colored dots represent significant genes (FDR<0.05). X-axis displays select CBMC cell types. N=3 samples per group. B. Dot plot of marker gene expression across monocyte cell clusters (CD14+ and CD16+). Y-axis displays marker genes, and X-axis displays cell clusters. Relative size of dots represents percentage of gene expression within a cell cluster, and relative color of dots represents average expression. C. Dot plot of highly variable genes in CD14+ and CD16+ monocytes between cases and controls. All significant genes FDR<0.05. Red indicates an increase in expression in cases, and blue indicates an increase in expression in controls. N=3 samples per group. D. Select Gene Ontology (GO; Biological Pathway) results for differentially expressed

genes between cases and controls in CD14+ Monocytes. GO categories have $FDR < 0.05$. X-axis indicates fold enrichment relative to the reference gene set of all expressed genes in the dataset. For a complete list of GO results, see Supplemental Table 1. E. Volcano plot of DGE between cases and controls in conventional dendritic cells (cDCs). Colored dots indicate statistical significance ($FDR < 0.05$). Positive $\log_2FC$ (pink dots) indicates higher expression in cases, and negative $\log_2FC$ (blue dots) indicates higher expression in controls. $N=3$ samples per group. F. Volcano plot of DGE between cases and controls in natural killer (NK) cells. Colored dots indicate statistical significance ($FDR < 0.05$). Positive $\log_2FC$ (pink dots) indicates higher expression in cases, and negative $\log_2FC$ (blue dots) indicates higher expression in controls. $N=3$ samples per group. G. Select Gene Ontology (GO; Biological Pathway) results for differentially expressed genes between cases and controls in NK. GO categories have $FDR < 0.05$. X-axis indicates fold enrichment relative to the reference gene set of all expressed genes in the dataset. For a complete list of GO results, see Supplemental Table 1.

Figure 3

A. Dot plot of marker gene expression across T cell clusters. Y-axis displays marker genes, and X-axis displays cell clusters. Relative size of dots represents percentage of gene expression within a cell cluster, and relative color of dots represents average expression. B. Volcano plot of DGE between cases and controls in CD8⁺ T cells. Colored dots indicate statistical significance (FDR<0.05). Positive log2FC (pink dots) indicates higher expression in cases, and negative log2FC (blue dots) indicates higher expression in controls. N=3 samples per group. C. Stacked bar plot of T cell receptor clones in cases and controls, with colors indicating the number of clones in a particular category. The difference in distribution of T cell clones between cases and controls is statistically significant (Kolmogorov-Smirnov Test p value 2.2e-16).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SuppTable1.xlsx](#)
- [SuppFig3.pdf](#)
- [SuppFig1.pdf](#)
- [SuppFig2.pdf](#)
- [SuppFig1.pdf](#)
- [SuppFig2.pdf](#)
- [SuppFig3.pdf](#)